These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 24396899)
1. Prostate help: a test that can help you avoid unnecessary prostate biopsies. When you've already had a biopsy and your PSA remains high, the PCA3 urine test can help you and your doctor to decide if another biopsy is really needed. Harv Mens Health Watch; 2013 Jul; 17(12):6. PubMed ID: 24396899 [No Abstract] [Full Text] [Related]
2. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? Ploussard G; Haese A; Van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Bastien L; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; Van Gils MP; Schalken JA; de La Taille A BJU Int; 2010 Oct; 106(8):1143-7. PubMed ID: 20230386 [TBL] [Abstract][Full Text] [Related]
3. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540 [TBL] [Abstract][Full Text] [Related]
4. Progensa™ PCA3 test for prostate cancer. Durand X; Moutereau S; Xylinas E; de la Taille A Expert Rev Mol Diagn; 2011 Mar; 11(2):137-44. PubMed ID: 21405964 [TBL] [Abstract][Full Text] [Related]
5. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Hessels D; van Gils MP; van Hooij O; Jannink SA; Witjes JA; Verhaegh GW; Schalken JA Prostate; 2010 Jan; 70(1):10-6. PubMed ID: 19708043 [TBL] [Abstract][Full Text] [Related]
6. PCA3: a molecular urine assay for predicting prostate biopsy outcome. Deras IL; Aubin SM; Blase A; Day JR; Koo S; Partin AW; Ellis WJ; Marks LS; Fradet Y; Rittenhouse H; Groskopf J J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257 [TBL] [Abstract][Full Text] [Related]
7. [Does PCA3 score and prostatic MRI help selection of patients scheduled for initial prostatic biopsy?]. Vinet M; Vlaeminck-Guillem V; Rouvière O; Perrin P; Paparel P; Devonec M; Adam E; Briant PE; Ruffion A Prog Urol; 2013 Feb; 23(2):121-7. PubMed ID: 23352305 [TBL] [Abstract][Full Text] [Related]
8. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322 [TBL] [Abstract][Full Text] [Related]
9. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644 [TBL] [Abstract][Full Text] [Related]
10. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492 [TBL] [Abstract][Full Text] [Related]
11. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209 [TBL] [Abstract][Full Text] [Related]
12. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709 [TBL] [Abstract][Full Text] [Related]